Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Codagenix/Serum Institute of India

Drug Profile

Coronavirus vaccine - Codagenix/Serum Institute of India

Alternative Names: 2019-nCoV vaccine - Codagenix; COVID-19 vaccine - Codagenix; SARS-CoV-2 Vaccine - Codagenix

Latest Information Update: 18 Feb 2020

At a glance

  • Originator Codagenix; Serum Institute of India
  • Developer Codagenix
  • Class Antivirals; Attenuated vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 19 Feb 2020 Serum Institute of India in collaboration with Codagenix plans a clinical trial in COVID-2019-infections in 2020
  • 13 Feb 2020 Codagenix and Serum Institute of India agree to co-develop Coronavirus vaccine for COVID-2019-infections
  • 13 Feb 2020 Early research in COVID-2019-infections (Prevention) in USA (Unspecified route)

Development Overview

Introduction

A live-attenuated vaccine against SARS-CoV-2 coronavirus is being developed by Codagenix in collaboration with Serum Institute of India for COVID-2019 infections. Codagenix will make use of its proprietary deoptimisation technology to synthesize the live-attenuated vaccine. The technology helps in generating multiple vaccine candidates against viruses and just requires the digital sequence of the viral genome. Viral genomes are processed by Codagenix’s computer-based algorithm for inducing multiple silent mutations into the genome to use codon pairs that are underrepresented in human cells. The genome that is de-optimised for translation in the human host cell is synthesised from scratch, assembled into a whole genome, transfected into cells and live, “de-optimised”, attenuated viruses are recovered for animal studies. The vaccine can be useful against multiple antigens of the virus and has the ability to scale for mass production. Early research is underway in the US.

Company Agreements

In February 2020, Codagenix entered into a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the COVID-2019 infections. Codagenix has designed multiple nCoV vaccine candidate genomes using its proprietary deoptimisation technology. The vaccine viruses will be grown and tested in vivo by contracted laboratories suitable for containment, prior to testing in clinical trials. The Serum Institute of India will then scale-up the manufacture of the vaccine to ensure its availability to meet a critical public health need. Codagenix and Serum Institute are pursuing an accelerated development pathway with built-in redundancies to increase speed and likelihood of success. [1]

Key Development Milestones

As of February 2020, Codagenix has designed several genomes for the coronavirus vaccine candidate [1] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Attenuated vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7 (Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA unspecified / unspecified Codagenix 13 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Codagenix Originator USA
Serum Institute of India Originator India
Serum Institute of India Owner India
Codagenix Owner USA

Future Events

Expected Date Event Type Description Updated
31 Dec 2020 Trial Update Serum Institute of India in collaboration with Codagenix plans a clinical trial in COVID-2019-infections in 2020 (319126) [2] 04 Mar 2020

Development History

Event Date Update Type Comment
19 Feb 2020 Trial Update Serum Institute of India in collaboration with Codagenix plans a clinical trial in COVID-2019-infections in 2020 [2] Updated 04 Mar 2020
13 Feb 2020 Licensing Status Codagenix and Serum Institute of India agree to co-develop Coronavirus vaccine for COVID-2019-infections [1] Updated 18 Feb 2020
13 Feb 2020 Phase Change Early research in COVID-2019-infections (Prevention) in USA (Unspecified route) [1] Updated 18 Feb 2020

References

  1. Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19.

    Media Release
  2. Serum Institute to be ready with coronavirus vaccine by 2022 .

    Media Release
Back to top